Results 41 to 50 of about 6,974,500 (303)

Mucormycosis infection in severe COVID‐19 patient with multiple underlying health conditions

Clinical Case Reports, 2021
Patients with underlying health conditions are vulnerable to invasive fungal infection following COVID‐19. It seems that uncontrolled diabetes mellitus makes patients susceptible to both severe COVID‐19 and mucormycosis.
Zahra Heydarifard, Moslem Safaei, Sevrin Zadheidar, Soroush Ehsan, Nazanin Zahra Shafiei‐Jandaghi   +4 more
doaj   +1 more source

Etoposide as Salvage Therapy for Cytokine Storm due to COVID-19

, 2020
Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators ...
Bromberg, Michael, Criner, Gerard J., 0000-0002-1828-6524, 0000-0003-2402-1351, Caricchio, Roberto, Patel, Maulin, Sacher, Daniel, Desai, Parag, Chandar, Ashwin, Dominguez Castillo, Eduardo, 0000-0002-1379-1118   +10 more
core   +1 more source

Necrotizing pneumonia due to Pseudomonas aeruginosa secondary to severe COVID‐19 pneumonia

Clinical Case Reports, 2023
Necrotizing pneumonia (NP) can occur as a secondary infection even if the clinical course of COVID‐19 pneumonia is favorable, particularly in patients on mechanical ventilation and under immunosuppression.
Jun Hirai, Nobuaki Mori, Nobuhiro Asai, Hiroshige Mikamo   +3 more
doaj   +1 more source

Phenotypical changes of hematopoietic stem and progenitor cells in COVID-19 patients: Correlation with disease status

Central European Journal of Immunology, 2023
Hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) play a crucial role in the context of viral infections and their associated diseases.
Hosni A. M. Hussein, Ali A. A. Thabet, Taha I. A. Mohamed, Mohamed E. Elnosary, Ali Sobhy, Ahmed M. El-Adly, Ahmed A. Wardany, Elsayed K. Bakhiet, Magdy M. Afifi, Usama M. Abdulraouf, Samah . M. Fathy, Noha G. Sayed, Asmaa M. Zahran   +12 more
doaj   +1 more source

Preliminary predictive criteria for COVID-19 cytokine storm

, 2020
Objectives: To develop predictive criteria for COVID-19-associated cytokine storm (CS), a severe hyperimmune response that results in organ damage in some patients infected with COVID-19.
Bromberg, Michael, 0000-0003-4737-8003, Criner, Gerard J., Zhang, Xinyan, Gallucci, Marcello, Dass, Chandra, Caricchio, Roberto, Gallucci, Stefania, Fleece, David, 0000-0002-1379-1118   +9 more
core   +1 more source

The effect of Fingolimod on patients with moderate to severe COVID‐19

Pharmacology Research & Perspectives, 2023
Hyper‐inflammation, cytokine storm, and recruitment of immune cells lead to uncontrollable endothelial cell damage in patients with coronavirus disease 2019 (COVID‐19).
Soheil Teymouri, Siamak Pourbayram Kaleybar, Seyyed Sina Hejazian, Seyyedeh Mina Hejazian, Khalil Ansarin, Mohammadreza Ardalan, Sepideh Zununi Vahed   +6 more
doaj   +1 more source

Impact of plasmapheresis on severe COVID-19

Scientific Reports, 2023
Abstract The clinical course of COVID-19 may show severe presentation, potentially involving dynamic cytokine storms and T cell lymphopenia, which are leading causes of death in patients with SARS-CoV-2 infection. Plasma exchange therapy (PLEX) effectively removes pro-inflammatory factors, modulating and restoring
G. Fonseca-González, M. Alamilla-Sánchez, V. García-Macas, J. Herrera-Acevedo, M. Villalobos-Brito, E. Tapia-Rangel, D. Maldonado-Tapia, M. López-Mendoza, J. H. Cano-Cervantes, J. Orozco-Vázquez, D. Timarán-Montenegro, S. Cortés-Martínez, M. Escarela-Serrano, S. Muñoz-López, L. Montiel-López, P. Mondragón-Terán, J. A. Suárez-Cuenca   +16 more
openaire   +3 more sources

Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

, 2022
BACKGROUND: The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear. DESIGN: ACTIV-6 is an ongoing, decentralized,
Boulware, David R., Stewart, Thomas G., Adam, Stacey J., Castro, Mario, Lindsell, Christopher J., Hanna, George, Ruiz-Unger, Juan, Singh, Upinder, Gentile|, Hernandez, Adrian F., Wilder, Rhonda, Thicklin, Florence, McTigue, Kathleen, Ginde, Adit A., Bramante, Carolyn, DeLong, Allison, Felker, G. Michael, Dolor, Rowena J., McCarthy, Matthew W., Wilson, Sybil, Sulkowski, Mark, Collins, Sean, Dunsmore, Sarah E., Jayaweera, Dushyantha, Remaly, April, Gentile, Nina, Naggie, Susanna, Shenkman, Elizabeth   +27 more
core   +1 more source

Mavrilimumab for severe COVID-19 [PDF]

The Lancet Rheumatology, 2020
Pourhoseingholi, Mohamad Amin, Shojaee, Sajad, Ashtari, Sara   +2 more
openaire   +5 more sources

CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

Frontiers in Medicine, 2023
IntroductionAutoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine.
Kevin Chevalier, Michaël Genin, Thomas Petit Jean, Jerôme Avouac, Rene-Marc Flipo, Sophie Georgin-Lavialle, Soumaya El Mahou, Edouard Pertuiset, Thao Pham, Amelie Servettaz, Hubert Marotte, Fanny Domont, Pascal Chazerain, Mathilde Devaux, Arsene Mekinian, Jérémie Sellam, Bruno Fautrel, Diane Rouzaud, Esther Ebstein, Nathalie Costedoat-Chalumeau, Christophe Richez, Eric Hachulla, Xavier Mariette, Raphaèle Seror   +23 more
doaj   +1 more source